Objective-Recent cohort studies have shown that nonalcoholic fatty liver disease (NAFLD), and especially nonalcoholic steatohepatitis (NASH), associate with atherosclerosis and cardiovascular disease, independently of conventional cardiometabolic risk factors. However, the mechanisms underlying the pathophysiological link between NAFLD/NASH and cardiovascular disease still remain unclear. Our previous studies have identified STK25 (serine/threonine protein kinase 25) as a critical determinant in ectopic lipid storage, meta-inflammation, and progression of NAFLD/NASH. The aim of this study was to assess whether STK25 is also one of the mediators in the complex molecular network controlling the cardiovascular disease risk. Approach and Results-Atherosclerosis was induced in Stk25 knockout and transgenic mice, and their wild-type littermates, by gene transfer of gain-of-function mutant of PCSK9 (proprotein convertase subtilisin/kexin type 9), which induces the downregulation of hepatic LDLR (low-density lipoprotein receptor), combined with an atherogenic western-type diet. We found that Stk25 −/− mice displayed reduced atherosclerosis lesion area as well as decreased lipid accumulation, macrophage infiltration, collagen formation, and oxidative stress in aortic lesions compared with wild-type littermates, independently from alterations in dyslipidemia. Reciprocally, Stk25 transgenic mice presented aggravated plaque formation and maturation compared with wild-type littermates despite similar levels of fasting plasma cholesterol. We also found that STK25 protein was expressed in all layers of the aorta, suggesting a possible direct role in cardiovascular disease. depletion or antisense oligonucleotide treatment effectively protects against diet-induced NASH. 15, 16, 18 Consistent with these results from mouse models, we also found that STK25 overexpression in human cultured hepatocytes increases lipid accumulation, impairs insulin action, and aggravates NASH features, such as alanine aminotransferase (ALT) secretion and oxidative damage, and the reciprocal effect is seen with STK25 knockdown.
C ardiovascular disease (CVD) continues to be a major cause of death in developed countries despite advances in lipid management therapy in the past years. Recently, attention has focused on the impact of nonalcoholic fatty liver disease (NAFLD) in the development and progression of CVD. NAFLD encompasses a wide spectrum of liver damage ranging from benign lipid accumulation (ie, steatosis) to nonalcoholic steatohepatitis (NASH), which is characterized not only by hepatic fatty infiltration but also by liver inflammation, fibrosis, and cellular damage in the form of ballooning and apoptosis. 1 It has long been known that patients with NASH are at high risk of progressing to cirrhosis, liver failure, and hepatocellular carcinoma. [2] [3] [4] A number of recent retrospective and prospective cohort studies have also shown that NAFLD, and especially NASH, associate with atherosclerosis and CVD, independently of conventional cardiometabolic risk factors. [5] [6] [7] [8] [9] [10] [11] [12] However, the mechanisms underlying the pathophysiological link between NAFLD/NASH and CVD still remain unclear.
Our translational studies in mouse models, human cell lines, and well-characterized patient cohorts have identified STK25(serine/threonine protein kinase 25), a member of the sterile 20 (STE20) kinase superfamily, 13 as a critical determinant in NASH. [14] [15] [16] [17] [18] We found that NASH induced by high-fat or methionine and choline-deficient diet is markedly exacerbated in mice overexpressing STK25 compared with their wild-type littermates, as evidenced by dramatic aggravation of steatosis, oxidative stress, inflammation, and nutritional fibrosis in the liver. 14, 15 Reciprocally, our studies showed that repression of STK25 activity in mice by genetic depletion or antisense oligonucleotide treatment effectively protects against diet-induced NASH. 15, 16, 18 Consistent with these results from mouse models, we also found that STK25 overexpression in human cultured hepatocytes increases lipid accumulation, impairs insulin action, and aggravates NASH features, such as alanine aminotransferase (ALT) secretion and oxidative damage, and the reciprocal effect is seen with STK25 knockdown. 15, 17 Furthermore, we observed that STK25 mRNA and protein levels correlate significantly and positively with progression of NASH in human liver biopsies, and several common nonlinked SNPs in the human STK25 gene are associated with altered liver fat. 15, 17, 18 We also showed both in human and mouse liver cells that STK25 coats the surface of intrahepatocellular lipid droplets. 14, 17 On the basis of our previous findings, which identify STK25 as a critical regulator of susceptibility to NASH, we hypothesized that STK25 is also one of the mediators in the complex and integrated molecular network controlling the CVD risk. Here, we studied the possible role of STK25 as a determinant of cardiovascular risk in a mouse model in which atherosclerosis was induced in Stk25 transgenic and knockout mice, and their wild-type littermates, by gene transfer of gainof-function mutant of PCSK9 (proprotein convertase subtilisin/kexin type 9) combined with an atherogenic western-type diet.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Mice
Whole-body Stk25 transgenic and knockout mice were generated and genotyped as previously described. 19, 20 In all experiments, Stk25 transgenic and knockout mice were compared with their corresponding wild-type littermates because the genetic background of these lines differs (C57BL6/N for Stk25 transgenic mice and C57BL6/J for Stk25 −/− mice; please see the Major Resources Table in the onlineonly Data Supplement). In this study addressing the effect of STK25 on atherosclerosis, only male mice were used because male mice are known to display less sex hormone variations, which might affect atherosclerosis progression. 21 However, studying a single sex has limitations because sex is a biological variable with known effects on human atherosclerotic disease and animal models of atherosclerosis, and the recent ATVB Council Statement suggests that all preclinical studies using atherosclerosis as an end point should be performed in both male and female mice. 21 Mice were weaned at 3 weeks of age and housed 3 to 5 per cage in a temperature-controlled (21°C) facility with a 12-hour light-dark cycle and free access to chow and water. Eight-week-old mice were given a tail-vein injection of the rAAV8-hPCSK9 D374Y virus (2×10 11 genome copies; kindly provided by Dr Juan A. Bernal, Madrid, Spain) 22 or saline control. Thereafter, mice were fed a western-type diet (21.2% fat and 0.2% cholesterol, TD.88137; Harlan Teklad, Madison, WI) for 12 weeks. At the age of 20 weeks, the mice were euthanized after withholding food for 4 hours. Blood was collected by heart puncture. Aorta and liver samples were collected for histomorphological analysis and snap frozen in liquid nitrogen and stored at −80°C for analysis of protein expression and biochemical assays (see Figure I in the online-only Data Supplement for a schematic overview). The mice received human care according to National Institutes of Health recommendations outlined in the Guide for the Care and Use of Laboratory Animals. All experiments were performed after prior approval from the local ethics committee.
Analysis of Aortic Lesions
Analysis of atherosclerotic lesions was performed following the American Heart Association Statement on experimental atherosclerosis studies. 23 The thoracic cavity was opened, and heart and aorta were perfused with PBS and removed. The aortic root was dissected and separated from the rest of the aorta at the brachiocephalic artery. It was then embedded in optimal cutting temperature mounting medium (Histolab Products, Gothenburg, Sweden) and frozen in liquid nitrogen for cryosectioning.
Aortic trees were opened longitudinally, pinned down on black silicone platform, and stained with Sudan IV (Sigma-Aldrich, St. Louis, MO) for lipids. En face images of aortic tree were captured, and lesion area was measured as a percentage of the total luminal area using the ImageJ software (ImageJ 1.47v; Wayne Rasband; National Institutes of Health, Bethesda, MD).
Aortic roots were sectioned (8 µm sections) starting from the commissures of the aortic cusps. Sections were stained with Oil Red O (Sigma-Aldrich) for lipids, Picrosirius Red (Histolab Products) for collagen, or dihydroethidium (Life Technologies, Grand Island, NY) to assess oxidative stress, or processed for immunofluorescence for STK25 or macrophage markers (please see the Major Resources Table in the online-only Data Supplement for antibody information). The area stained in histological sections was quantified in 5 randomly selected X20 microscopic fields per mouse using the ImageJ software, except for Oil Red O-stained sections, where the area stained was quantified in full sections form 3 different levels of aortic roots (0, 80, and 160 µm after the commissures of the aortic cusps). For statistical analysis, we first calculated a mean value of the area stained per each mouse based on the fields/sections analyzed. The subsequent statistical group comparisons were then performed on these averages.
Liver Histology and Immunofluorescence
Liver samples were fixed with 4% v/v phosphate-buffered formaldehyde (Histolab Products), embedded in paraffin, sectioned (8 µm sections), and stained with hematoxylin and eosin or Picrosirius Red (Histolab Products). Sections were also processed for immunofluorescence for Gr1(Ly6C), F4/80, or collagen type I (please see the Major Resources Table in the online-only Data Supplement for antibody information). The area stained with Gr1(Ly6C), F4/80, or collagen type I was quantified in 5 randomly selected ×20 microscopic fields per mouse using the ImageJ software. For statistical analysis, we first calculated a mean value of the area stained per each mouse based on the fields analyzed. The subsequent statistical group comparisons were then performed on these averages.
In hematoxylin and eosin-stained sections, 10 randomly selected ×200 microscopic fields per mouse were assessed for NAFLD activity score (NAS) according to the Kleiner/Brunt criteria. [24] [25] [26] [27] In sections stained with Picrosirius Red, 10 randomly selected ×200 microscopic fields per mouse were assessed for fibrosis score according to the Kleiner/Brunt criteria. 24, 25, 28 The statistical group comparisons were performed as described above.
Biochemical Assays
Plasma levels of human and mouse PCSK9 were measured using the human and mouse PCSK9 Quantikine ELISA Kits, respectively (R&D Systems, Minneapolis, MN). Plasma cholesterol was assessed using the Total Cholesterol and Cholesteryl Ester Colorimetric Assay Kit II (BioVision, Mountain View, CA). Plasma lipoproteins were separated in pooled samples from each group by size-exclusion chromatography, and cholesterol was quantified with a system of detection online as described. 29 The plasma alanine and aspartate aminotransferase (ALT/AST) levels were determined using the ALT Activity Assay Kit (Cayman Chemical, Ann Arbor, MI) and AST Activity Assay Kit (Sigma-Aldrich), respectively. Liver lipids were extracted using the BUME (butanol/methanol) method 30 and quantified using straight-phase high-performance liquid chromatography as described previously. 31 To measure hepatic collagen content, liver samples were homogenized in distilled water, hydrolyzed in 12 N HCl for 3 hours at 120°C, and analyzed using a Hydroxyproline Assay Kit (Sigma-Aldrich).
Western Blot Analysis
Western blot was performed as previously described 20 (please see the Major Resources Table in the online-only Data Supplement for antibody information).
Statistical Analysis
Statistical significance between the groups was evaluated using the 2-sample Student t test, and among >2 groups by 1-way ANOVA followed by a 2-sample Student t test for post hoc analysis. The Shapiro-Wilk and the Levene tests were applied to confirm the normality of distribution of residuals and the homogeneity of variances, respectively. In cases where variances were found to be unequal, Welch t test was used in assessing statistical significance. For data collected from same mice at different time points [applies to the measurement of plasma cholesterol ( Figures 1C and 5C ) and plasma ALT and AST activity ( Figures 1D, 1E , 5D, and 5E)], a repeated measurement ANOVA with group, time, and group*time as fixed effects and a compound symmetry covariance structure was used for analysis. Differences were considered statistically significant at a P value <0.05. All statistical analyses were performed using SPSS Statistics (v24; IBM Corporation, Armonk, NY).
Results

Overexpression of STK25 in Mice Increases Diet-Induced Atherogenesis Susceptibility
In this study, we induced atherosclerosis in mice by viral transduction of the liver with an adeno-associated virus (rAAV8) carrying the Asp374 to Tyr gain-of-function mutation in human PCSK9 (hPCSK9
D374Y
). This mutation increases the affinity of PCSK9 for the LDLR (low-density lipoprotein receptor) by ≥10-fold, 32 which has been demonstrated to robustly induce the post-translational downregulation of hepatic LDLR, causing long-term hypercholesterolemia and subsequent atherosclerosis in mice when combined with an atherogenic western-type diet. 22, [33] [34] [35] [36] We found that a single intravenous injection of adult Stk25 transgenic mice and their wild-type littermates with rAAV8-hPCSK9 D374Y resulted in high plasma levels of human PCSK9 protein when measured at 12 weeks post-injection ( Figure 1A ). Consistently, we observed markedly decreased hepatic LDLR protein levels in hPCSK9 D374Y -transduced Stk25 transgenic and wild-type mice compared with saline-injected controls at 12 weeks postinjection ( Figure 1B) . Interestingly, we also found increased endogenous mouse PCSK9 protein levels in plasma samples of mice at 12 weeks after injection with rAAV8-hPCSK9 D374Y ( Figure IIA in the online-only Data Supplement). This result has been reported by other research groups 22 and indicates that when the hPCSK9 D374Y is present, the rate of endogenous mouse PCSK9 protein turnover is slower than normal.
Furthermore, rAAV8-hPCSK9 D374Y injection significantly increased fasting plasma cholesterol levels in mice maintained on a western-type diet; 12 weeks after injection, total cholesterol in hPCSK9 D374Y -transduced Stk25 transgenic and wild-type mice was 3.6±0.7-and 4.0±0.5-fold higher compared with that in saline-treated control mice, respectively, demonstrating the chronic effect of single injection on systemic lipid levels in both genotypes ( Figure 1C ). Examining cholesterol distribution across the lipoprotein fractions separated by size-exclusion chromatography also revealed marked increase in very-low-density lipoprotein/remnant total cholesterol and reduction in high-density lipoprotein total cholesterol in rAAV8-hPCSK9 Consistent with previous reports, 37, 38 we found that rAAV8 viral infection did not elicit any adverse responses in the liver, and postinjection plasma levels of hepatic enzymes ALT and AST were not increased compared with those of uninfected mice ( Figure 1D and 1E). Interestingly, we found that plasma levels of AST were significantly lower in rAAV8-hPCSK9 Mice were euthanized after 12 weeks of feeding with a western-type diet to quantify atherosclerosis progression. The en face analysis of aortic tree stained with Sudan IV showed that rAAV8-hPCSK9 D374Y -injected wild-type mice had developed fatty streak lesions, which covered 2.3±0.4% of luminal surfaces, whereas hPCSK9 D374Y -transduced Stk25 transgenic mice developed significantly more fatty streaks lesions, which covered 4.9±0.9% of luminal surface; saline-treated control mice showed minimal lesion development (1.1±0.2% of luminal surfaces; Figure 2A ). Consistent with this finding, the quantitative analysis of the cross-sectional area of plaques at the level of the aortic sinus revealed that the atherosclerotic lesion area (Oil Red-O-positive) was significantly increased in both groups injected with rAAV8-hPCSK9 D374Y ; however, we observed significantly larger plaques in the hPCSK9 Injection of Stk25 (serine/threonine protein kinase 25) transgenic mice and their wild-type littermates with rAAV8-hPCSK9 D374Y increased human PCSK9 (proprotein convertase subtilisin/kexin type 9) protein levels in the plasma, decreased LDLR (low-density lipoprotein receptor) protein abundance in the liver, and aggravated plasma cholesterol without any signs of hepatotoxicity. A, Plasma levels of human PCSK9 protein (n=7 per group). B, Liver protein lysates were analyzed by Western blot using antibodies specific for LDLR. Protein levels were analyzed by densitometry with values in saline-injected wildtype mice set to 1 (n=7-8 per group). Representative Western blots are shown with actin used as a loading control. C, Measurement of plasma cholesterol levels (n=7-8 per group). D and E, Measurement of plasma alanine aminotransferase (D) and aspartate aminotransferase activity (E) with values in salineinjected wild-type mice at each time point set to 1 (n=7-8 per group). Data are mean±SEM. *P<0.05, **P<0.01, ##P<0.01 for saline-vs rAAV8-hPCSK9 D374Y -injected wild-type mice; § §P<0.01 for saline-injected wild-type mice vs rAAV8-hPCSK9 D374Y -injected Stk25 transgenic mice. TG indicates transgenic; and WT, wild type.
adhesion on the endothelium, infiltration into the subendothelial space, and localization in the artery wall are the critical initial steps of plaque formation. 39 Blood monocytes in mice are mainly in 2 subsets, Gr1(Ly6C) lo and Gr1(Ly6C) hi subsets; the latter is considered inflammatory and homes to inflamed tissues. [40] [41] [42] Notably, we found a higher level of macrophage infiltration in the aorta, as assessed by Gr1(Ly6C)-and CD68-positive staining, in hPCSK9 Stk25 transgenic mice compared with wild-type controls ( Figure 2E ). We also found evidence of increased oxidative stress in the aorta as dihydroethidium staining, which quantifies superoxide radicals (O 2 saline-injected wild-type controls, when all the groups were fed a western-type diet ( Figure 3A) . Histological examination of hematoxylin and eosin-stained liver sections further confirmed that, in contrast to low-grade steatosis observed in wild-type mice after western-type diet feeding, pronounced macrovesicular steatosis, accompanied by excessive microvesicular steatosis, was seen in Stk25 transgenic mice, where the majority of hepatocytes were tightly packed with moderateto-large-sized lipid droplets ( Figure 3B ). We also found increased presence of macrophages in the liver sections from hPCSK9 D374Y -transduced Stk25 transgenic versus wild-type mice as evidenced by enhanced staining for Gr1(Ly6C) 43 and F4/80 ( Figure 3C and 3D) . Furthermore, liver fibrosis was aggravated in hPCSK9 D374Y -transduced Stk25 transgenic mice as revealed by immunofluorescence analysis for collagen type I ( Figure 3E ) and staining with Picrosirius Red (stains both collagen type I and type III; Figure 3F ). Consistently, hepatic hydroxyproline content, a marker of collagen deposition, was ≈1.3±0.1-fold higher in liver lysates from Stk25 transgenic mice ( Figure 3G ).
The liver pathology was also evaluated by using the NAFLD activity score (NAS; ie, steatosis, lobular inflammation, and hepatocellular ballooning scores) and fibrosis score adapted to rodents according to the Kleiner/Brunt criteria. [24] [25] [26] [27] [28] We found that liver steatosis and hepatocellular ballooning, as well as total NAS, were significantly higher in hPCSK9 D374Y -transduced Stk25 transgenic mice compared with the both wild-type groups, although no significant differences were observed in scoring for inflammatory foci ( Figure 4A and 4B) . Furthermore, hPCSK9 D374Y -transduced Stk25 transgenic mice scored significantly higher for liver fibrosis ( Figure 4C ).
Acetyl-CoA carboxylase (ACC) is one of the key controllers of ectopic lipid storage in the liver; ACC activity is regulated by phosphorylation, where kinases such as AMPK (AMP-activated protein kinase) directly phosphorylate and inactivate ACC. 44 Here, we found that the total protein abundance of ACC was significantly increased in the livers of hPC-SK9 D374Y -transduced Stk25 transgenic mice compared with the both wild-type groups, whereas the level of phospho-ACC was not altered (Figure VIA in the online-only Data Supplement).
Depletion of STK25 in Mice Protects Against Diet-Induced Atherosclerosis
Similarly to our findings in Stk25 transgenic cohorts, a single intravenous injection with rAAV8-hPCSK9 D374Y resulted in high plasma levels of human PCSK9 protein and correspondingly, a markedly decreased hepatic LDLR protein abundance, in Stk25 knockout mice and their wild-type littermates compared with saline-injected control mice when analyzed at 12 weeks post-injection ( Figure 5A and 5B). Again, we also found increased endogenous mouse PCSK9 protein levels in A B C littermates with rAAV8-hPCSK9 D374Y increased human PCSK9 (proprotein convertase subtilisin/kexin type 9) protein levels in the plasma, decreased LDLR (low-density lipoprotein receptor) protein abundance in the liver and aggravated plasma cholesterol without any signs of hepatotoxicity. A, Plasma levels of human PCSK9 protein (n=6-8 per group). B, Liver protein lysates were analyzed by Western blot using antibodies specific for LDLR. Protein levels were analyzed by densitometry with values in salineinjected wild-type mice set to 1 (n=7-10 per group). Representative Western blots are shown with actin used as a loading control. C, Measurement of plasma cholesterol levels (n=6-9 per group). D and E, Measurement of plasma alanine aminotransferase (ALT; D) and aspartate aminotransferase (AST) activity (E) with values in saline-injected WT mice at each time point set to 1 (n=6-9 per group). Data are mean±SEM. **P<0.01; ##P<0.01 for saline-injected vs rAAV8-hPCSK9 Twelve-week feeding of a western-type diet increased fasting plasma cholesterol levels in rAAV8-hPCSK9
D374Y -injected
Stk25
−/− and wild-type mice from 140.8±4.9 to 911.1±124.3 mg/dL and 132.5±9.2 to 920.1±87.3 mg/dL, respectively, without any difference between the genotypes ( Figure 5C ). Saline-injected wild-type mice that consumed a western-type diet had only a small change in total cholesterol (week 0: 140.9±9.3 mg/dL; week 12: 261.9±22.2 mg/dL; Figure 5C ).
Examining cholesterol distribution across the lipoprotein fractions also revealed marked increase in very-low-density lipoprotein/remnant and LDL total cholesterol and reduction in high-density lipoprotein total cholesterol in rAAV8-hPC-SK9 D374Y -injected mice compared with saline-injected controls without any difference between hPCSK9 The en face analysis of aortic tree performed after 12 weeks of western-type diet feeding demonstrated that hPC-SK9
D374Y -transduced Stk25
−/− mice displayed significantly less Sudan IV-positive fatty streaks lesions compared with hPCSK9 D374Y -transduced wild-type littermates (3.1±0.3% versus 4.6±0.5% of luminal surfaces, respectively), although the lesion area was higher in both these groups compared with saline-injected control mice (1.0±0.3% of luminal surfaces; Figure 6A ). Analysis of Oil Red O-stained cross-sections of the aortic sinus also revealed small plaques in saline-injected mice and larger lesions in rAAV8-hPCSK9 Figure 6B ). To investigate potential mechanisms leading to decreased lesion size in Stk25 −/− mice, we analyzed atherosclerotic plaque cell composition and damage from oxidative stress. We observed that depletion of STK25 markedly restrained the infiltration of macrophages into the artery wall as assessed by reduced Gr1(Ly6C)-and CD68-positive staining ( Figure 6C and 6D ).
Collagen deposition within the lesions was also significantly lower in hPCSK9 D374Y -transduced Stk25 knockout versus wildtype mice ( Figure 6E ). Furthermore, we found a tendency for reduced oxidative stress in the aorta from Stk25 −/− mice as evidenced by ≈2-fold lower dihydroethidium staining ( Figure 6F ).
Stk25
−/− Mice Fed a Western-Type Diet Are Protected Against NAFLD Development
We observed significantly reduced accumulation of triacylglycerol in the liver lysates from hPCSK9 D374Y -transduced Stk25 knockout mice compared with both rAAV8-hPC-SK9 D374Y -injected or saline-injected wild-type controls, when all the groups were fed a western-type diet ( Figure 7A) . Consistently, microscopic examination of hematoxylin and eosin-stained liver sections revealed that Stk25 −/− mice were protected against hepatic steatosis triggered by western-type diet feeding ( Figure 7B ). We also found that the inflammatory infiltration in the liver assessed by staining for Gr1(Ly6C) and F4/80, and hepatic fibrosis measured by staining for collagen type I and Picrosirius Red, as well as by biochemical assessment of hydroxyproline content, were markedly lower in hPCSK9
D374Y
-transduced Stk25 knockout versus wild-type mice ( Figure 7C through 7G) .
Furthermore, NAS scoring demonstrated that liver steatosis and hepatocellular ballooning, as well as total NAS, were significantly reduced in hPCSK9
-transduced Stk25 knockout mice compared with the both wild-type groups, although no significant differences were observed in scoring for inflammatory foci ( Figure 8A and 8B) . Consistently, hPC-SK9
D374Y -transduced Stk25
−/− mice scored significantly lower for liver fibrosis ( Figure 8C ).
Reciprocally to our observations in Stk25 transgenic mice, we found that the total protein abundance of ACC was significantly reduced in the livers of hPCSK9 
STK25 Protein Is Expressed in All Layers of the Aorta
STK25 is broadly expressed in mouse, rat, and human tissues, including liver, skeletal muscle, and adipose tissue 16, 20, 45 ; however, it is not known whether STK25 is also present in the vascular system. Here, we determined the expression of STK25 by immunofluorescence analysis in aortic root samples collected after 12 weeks of western-type diet feeding. In wild-type mice, endogenous STK25 protein could be detected homogenously throughout the intima, media, and adventitia without any difference comparing the saline-or rAAV8-hPC-SK9 D374Y -injected mice, and this expression was augmented in transgenic mice ( Figure 9 ). Specificity of the staining was confirmed by lack of positive signal in aortic root sections from Stk25 −/− mice ( Figure 9 ). Notably, we also found that both human aortic endothelial cells and human aortic smooth muscle cells express high levels of endogenous STK25 protein ( Figure VII in the online-only Data Supplement).
Discussion
This study provides evidence that protein kinase STK25 has a critical role in CVD. We found that STK25 depletion in LDLR-deficient mice resulted in reduced atherosclerosis lesion area and decreased lipid accumulation, macrophage infiltration, and collagen formation in aortic lesions compared with LDLR-deficient wild-type littermates when both genotypes were on an atherogenic western-type diet. Reciprocally, LDLR-deficient Stk25 transgenic mice on a western-type diet displayed aggravated plaque formation and maturation compared with LDLR-deficient wild-type control mice ( Figure 10 ). The findings of this study are consistent with our previous investigations in liver, skeletal muscle, and pancreas, where STK25 also critically controls ectopic lipid deposition, meta-inflammation, and nutritional fibrosis in mice under conditions of excess dietary fat. [14] [15] [16] [17] [18] 20, 46, 47 Mice with germline depletion of LDLR or APOE (apolipoprotein E) have long been the preferred preclinical models for studying atherosclerosis. In this study, we induced atherosclerosis in mice by adenoviral transduction of a gain-of-function mutant (D374Y) of human PCSK9, which results in post-translational degradation of LDLR in the liver; this recently described method circumvents the need for time-consuming cross-breeding. 22, [33] [34] [35] [36] We found that a single injection of rAAV8-hPCSK9 D374Y into Stk25 −/− or transgenic mice on a western-type diet resulted in a similar degree of severe hypercholesterolemia when compared with their corresponding wild-type littermates. However, we also observed that rAAV8-hPCSK9 D374Y injection resulted in higher fasting plasma cholesterol levels in Stk25 transgenic line compared with Stk25 knockout line. The reason for this observation is not known, but different genetic backgrounds of Stk25 transgenic versus knockout lines might have contributed to this variance. Importantly, because of different genetic backgrounds, we have only compared Stk25 −/− and transgenic mice with their corresponding wild-type littermates in this study.
Similarly to our previous findings in the liver of mice fed a pelleted high-fat (45 kcal% fat) or methionine and cholinedeficient diet, [14] [15] [16] 18 we here observed that hepatic steatosis was reduced in hPCSK9 D374Y -transduced Stk25 −/− mice and increased in Stk25 transgenic mice compared with wild-type littermates, when all the groups were fed a western-type diet. Our previous studies in hepatocytes of both mouse and human origin have revealed that depletion of STK25 enhances β-oxidation, whereas STK25 overexpression promotes reciprocal change, 14, 17 thus providing a likely mechanism for STK25 to regulate liver lipid retention. We have also previously reported that hepatic ACC protein abundance is significantly reduced in high-fat diet-fed mice where STK25 activity is repressed by genetic depletion or antisense oligonucleotide treatment, whereas ACC levels are higher in the livers of high fat-fed Stk25 transgenic mice compared with the corresponding control Figure 9 . STK25 (serine/threonine protein kinase 25) is expressed in all layers of the aorta. Representative images of aortic roots processed for immunofluorescence using anti-STK25 (red); nuclei stained with DAPI (4',6-diamidino-2-phenylindole; blue). Bars=200 µm for ×5 and 50 µm for ×20. hPCSK9 indicates human proprotein convertase subtilisin/kexin type 9; KO, knockout; TG, transgenic; and WT, wild type. groups of mice. 16, 18, 20 This provides a likely mechanism underlying the observed changes in β-oxidation because the enzymatic product of ACC, malonyl-CoA, represses long-chain fatty acylCoA uptake and oxidation in mitochondria through allosteric inhibition of carnitine palmitoyltransferase. 48 Consistent with these previous investigations, we here found that hPCSK9 D374Y -transduced Stk25 −/− and transgenic mice fed a western-type diet displayed suppressed and increased hepatic ACC protein abundance, respectively, suggesting that STK25 regulates ACC levels independently of the type of dietary challenge.
The characteristics of NAFLD (ie, liver steatosis, inflammation, and fibrosis) are known to increase the risk for atherosclerosis and CVD. 1 However, the findings of this study do not allow us to definitely conclude whether STK25 regulates the susceptibility to atherosclerosis in mice through its effect on the liver or by a direct action in the aorta. Notably, we found that both endogenous STK25 and STK25 overexpressed in transgenic mice were present in all layers of the aorta, consistent with the possibility that STK25 may influence plaque formation and maturation through a direct effect in the aorta. Furthermore, the levels of fasting plasma cholesterol were similar in hPCSK9 D374Y -transduced Stk25 −/− or transgenic mice when compared with their corresponding wild-type littermates, suggesting that the effect of STK25 on plaque formation was not attributable to alterations in liver lipid secretion resulting from different levels of hepatic triacylglycerols.
We have previously reported that decreased STK25 abundance in both mouse liver and human hepatocytes protects against oxidative damage and that STK25 overexpression aggravates oxidative stress, 14, 15 suggesting that oxidative injury is one of the factors involved in STK25-regulated NAFLD progression. Consistent with these results, here we found that the aorta of hPCSK9
D374Y -transduced Stk25
−/− and transgenic mice displayed reduced and increased staining for dihydroethidium (a marker for cellular superoxide radicals), respectively. Oxidative stress induced by generation of excess reactive oxygen species has emerged as a critical mechanism in atherosclerosis. 49 Almost all risk factors for CVD (eg, hypertension, diabetes mellitus, smoking, and dyslipidemia) promote a state of oxidative stress, and multiple gene polymorphisms in the oxidative stress pathway genes have been found to modify the risk of atherosclerosis. 50 Furthermore, drugs such as aspirin, statins, and reninangiotensin system inhibitors, which are already used clinically to treat atherosclerotic vascular disease, exert pleiotropic antioxidative effects. [51] [52] [53] [54] Intense research efforts to identify new therapeutic modalities that selectively target oxidative stress in atherosclerosis and NASH are ongoing, and we speculate that STK25 might be one of the factors in the complex network of mediators regulating oxidative damage in different organs.
The main focus of this study was to investigate the possible role of STK25 in regulation of CVD risk in a mouse model of hypercholesterolemia to mimic conditions in highrisk individuals. Therefore, we have primarily compared the atherosclerosis progression in Stk25 knockout mice versus their wild-type littermates injected with rAAV8-hPCSK9 , when all the groups were maintained on a western-type diet. However, this study does not allow us to investigate whether STK25 would have any impact on atherosclerosis progression in mice displaying normal LDLR levels, which is the limitation of the study design. Notably, whereas the phenotypes across the studied strains are consistent with a role for STK25 in atherosclerosis, we have not been able to characterize the mechanism of action of STK25, or its potential substrates, in the artery wall. Interestingly, we found that both human aortic endothelial cells and aortic smooth muscle cells express high levels of endogenous STK25 protein, making them suitable for mechanistic experiments using RNA interference and transient overexpression, which will be the focus of our future studies.
Atherosclerosis is the major cause of coronary heart disease and the leading cause of morbidity and mortality in western society. However, therapeutic strategies to alleviate atherosclerosis associated with the metabolic syndrome remain sparse. The results of this study demonstrate that depletion of STK25 effectively attenuates the formation of diet-induced atherosclerosis lesions in the context of obesity in mice independently from alterations in dyslipidemia. Furthermore, Stk25 knockout mice displayed beneficial changes in lesion composition, including less Gr1(Ly6C) hi monocyte infiltration and collagen formation, which are characteristic of less mature lesions. These results suggest that pharmacological intervention aimed at reducing STK25 function may provide new preventive and therapeutic possibilities for atherosclerosis.
